pretickt

Is BSX a good stock to buy?

Boston Scientific Corporation · end-of-day data as of Nov 13, 2026

Boston Scientific
BSX · $64.27B
$44.34+0.3%
Nov 13, 2026 · close
$45$50SepOctNov9:3016:003 months -12.1%Nov 13 · close
▲ 9
  • PT$54.04 +21.9%
  • ConsensusBuy · 32
  • P/E vs own-32.6%
  • P/E vs sector-41.7%
  • FCF yield+5.2%
  • Insiders$100K
  • MA20×50Golden 3d ago
  • MACD0.07
  • Sector▲ +15.9%
Neutral
  • Earnings in82d
  • P/E18.8x
  • RSI50
  • Support-4.2%
  • Resistance+2.6%
  • Off 52w high-57.6%
  • Volume0.5x
  • Bollingerlower half
  • 52w range$40–$105
  • ATR+3.8%
  • Off ATH-59.5%
▼ 3
  • News
  • Trendbearish
  • MAs1 of 4

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is Boston Scientific a good stock to buy?

Boston Scientific is strong on 4 of the 5 questions about the business. The price is low: 18.8 times its earnings, below its 3-year median of 55.6 (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand growing
  2. Advantage some edge
  3. Economics profits growing
  4. Execution delivers
  5. Fragility sturdy
  6. Price below its usual
DemandDo people want more of what it sells?growing

BSX sales growth revenue growth

+17%a year, for the last 3 years

Boston Scientific's sales grew 17% a year for 3 years, to $20.07B in fiscal 2025.

BSX analysts' forecast revenue estimates

+4%the sales they expect next fiscal year, on the last

Analysts expect Boston Scientific's sales to grow 4% to $20.97B in fiscal 2026 (21 analysts).

BSX competitors

pretickt analysis+9%its sales in 12 months, on a year before

Boston Scientific's sales grew 9% in the 12 months to Sep 30, 2026, faster than Stryker (+8%) and GE HealthCare (+2%), slower than Edwards Lifesciences (+13%).

BSX sales by business revenue by segment

66%of its sales from Cardiovascular

Cardiovascular brought Boston Scientific 66% of its sales in fiscal 2025; MedSurg 34%.

Advantage moatIs it hard to copy?some edge

BSX margin on each sale gross margin

70%left after making the product

Boston Scientific kept 70% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 66%.

EconomicsDoes it make good money?profits growing

BSX profit per share

+55%in its last fiscal year

Boston Scientific's earnings per share grew 55% in fiscal 2025, to $1.93.

ExecutionDoes it deliver what it promises?delivers

BSX earnings vs estimates

8 of 8quarters above the analysts' estimate

Boston Scientific beat the analysts' profit estimate in each of its last 8 quarters, the latest on Oct 28, 2026.

BSX insider selling

-$6.76Msold, net, by its executives in 12 months

Boston Scientific's executives and directors sold a net $6.76M of shares in the 12 months to Nov 13, 2026 ($16.8M sold, $10.04M bought).

BSX number of employees

+11%more people in a year

Boston Scientific had 59,000 employees at the end of fiscal 2025, 11% more than a year before.

BSX CEO pay

$23.53Mfor fiscal 2025, 74% of it in stock and options

Boston Scientific paid its CEO $23.53M for fiscal 2025, 74% of it in stock and options.

Fragility risksCould something break it?sturdy

BSX financial health Altman Z-score

3.1Altman Z-score, safe above 3

Boston Scientific's Altman Z-score is 3.1 (Nov 13, 2026), above 3, where the safe zone starts.

BSX quality checks Piotroski score

8 of 9checks passed

Boston Scientific passes 8 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on the current ratio.

BSX biggest customers

under 10%of sales from any one customer

No customer made 10% of Boston Scientific's sales in fiscal 2025.

BSX in past recessions

pretickt analysis-8%its sales in the worst one

Boston Scientific's sales fell in each of the last 2 US recessions, by as much as 8% in fiscal 2020.

Price valuationIs the price reasonable?below its usual

BSX price vs profit P/E ratio

18.8×a year's earnings

Boston Scientific's P/E ratio is 18.8 (Nov 13, 2026), below its 3-year median of 55.6.

BSX price vs competitors

pretickt analysis18.8×a year's earnings, against its competitors

Investors pay 18.8 times Boston Scientific's earnings (Nov 13, 2026), less than for Edwards Lifesciences (60.5), Stryker (33.0) or GE HealthCare (21.7).

BSX analysts' target price target

+22%to their average target

Analysts' average price target for Boston Scientific is $54.04, 22% above the Nov 13, 2026 close of $44.34.

BSX analyst ratings, 90 days

pretickt analysis
  • Citigroupdowngrade
  • Jefferiesdowngrade
  • TD Cowendowngrade
0 up, 3 downratings raised and cut

In the 90 days to Nov 13, 2026, Citigroup, Jefferies and TD Cowen downgraded Boston Scientific.

What is Boston Scientific's P/E ratio?

Boston Scientific's P/E ratio is 18.8 (Nov 13, 2026), below its 3-year median of 55.6. Investors pay 18.8 times Boston Scientific's earnings (Nov 13, 2026), less than for Edwards Lifesciences (60.5), Stryker (33.0) or GE HealthCare (21.7).

Who are Boston Scientific's biggest competitors?

pretickt compares Boston Scientific with Edwards Lifesciences, GE HealthCare, Stryker and Medtronic. Boston Scientific's sales grew 9% in the 12 months to Sep 30, 2026, faster than Stryker (+8%) and GE HealthCare (+2%), slower than Edwards Lifesciences (+13%).

Are insiders selling Boston Scientific stock?

Boston Scientific's executives and directors sold a net $6.76M of shares in the 12 months to Nov 13, 2026 ($16.8M sold, $10.04M bought).

How does Boston Scientific make money?

Cardiovascular brought Boston Scientific 66% of its sales in fiscal 2025; MedSurg 34%.

How many employees does Boston Scientific have?

Boston Scientific had 59,000 employees at the end of fiscal 2025, 11% more than a year before.

Who are Boston Scientific's biggest customers?

No customer made 10% of Boston Scientific's sales in fiscal 2025.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.